netFormulary

North East and North Cumbria
ICS Formulary

9 Nutrition and blood

09-05-01-02 Hypercalcaemia and hypercalciuria

Zoledronic Acid Zometa®

First Choice

4mg injection
For hypercalcaemia of malignancy and the prevention of skeletal events in patients with metastatic breast cancer. Prescribe by brand name (Zometa®) to avoid confusion with a different strength product used to treat osteoporosis and Paget’s disease

Cinacalcet

Formulary

Approved for the treatment of secondary hyperparathyroidism in patients with end stage renal disease on maintenance haemodialysis where parathyroid gland surgery has failed or is inappropriate.

Also for short term use to control symptoms prior to a second attempt at more definitive surgery.

Approved for patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated based on serum calcium levels, symptoms and end organ damage, but in whom parathyroidectomy is either not clinically appropriate or is contraindicated. It is not normally commissioned if serum calcium concentration is <2.85mmol/L

Disodium Pamidronate

Formulary

Etelcalcetide Parsabiv^®

Formulary

2.5mg/0.5ml, 5mg/1ml & 10mg/2ml solution for injection
Approved for the treatment of secondary hyperparathyroidism in line with NICE and NHS England Commissioning Policy

Paricalcitol

Formulary

Approved for use in patients with PTH levels < 800mcg/l but whose treatment with alfacalcidol is restricted due to a high calcium level.

Calcitonin Salmon^®

Formulary

Sodium Clodronate

Formulary

Links